Compare Schwab US Large Cap Growth ETF (SCHG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs TG Therapeutics Inc — how do they compare? Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 8× TG Therapeutics Inc's market cap, and Schwab US Large Cap Growth ETF is more actively traded (8,554,399 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and TG Therapeutics Inc for 16 Days on average.
| SCHG | TGTX | |
|---|---|---|
Market Cap | $65.01B | $8.16B |
Volume | 8,554,399 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $59.06 |
52-Week Low | $28.10 | $26.94 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $36.72, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's role in growth portfolios and tax-efficient strategies, with Seeking Alpha noting its valuation discount compared to QQQM as of September 9, 2026.
SCHG offers exposure to large-cap growth stocks with competitive fees, though concentration in top holdings presents both opportunity and risk. The ETF's performance is closely tied to megacap technology names, making it sensitive to sector rotations. Long-term growth potential remains supported by historical outperformance, but investors should monitor holding concentration and market leadership shifts.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
